Author

A. C. Walls

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 20 Biochemistry· 6 Microbiology· 5 Evolutionary Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 30 Research Focus:host-pathogen & immune response· 22 Organism:human· 17 Assay:proteomics· 12 Research Focus:drug response / drug discovery· 8 Organism:mouse· 5 Organism:virus· 5 Research Focus:cell type annotation· 4

Frequent Co-Authors

D. Veesler· 27 shared J. E. Bowen· 17 shared D. Corti· 13 shared M. A. Tortorici· 13 shared D. Pinto· 8 shared E. Cameroni· 8 shared G. Snell· 8 shared Y.-J. Park· 8 shared

Activity by Year

2016-2024 · peak 14/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

27 shared papersImmunology

D. Veesler

Mutual co-authors in cluster

Author profile →

32 papers

Recent·Most cited

Protein nanoparticle vaccines induce potent neutralizing antibody responses against MERS-CoV

C. W. Chao, K. R. Sprouse, M. C. Miranda, N. J. Catanzaro, M. L. Hubbard, A. Addetia, C. Stewart, J. T. Brown, A. Dosey, A. Valdez, R. Ravichandran, G. G. Hendricks, M. Ahlrichs, C. Dobbins, A. Hand, , N. P. King

This study develops MERS-CoV vaccines using a protein nanoparticle platform, showing they induce strong neutralizing antibodies and protect mice against MERS-CoV challenge.

bioRxiv · Mar 13, 2024Immunology

Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape

R. Marzi, J. Bassi, C. Silacci-Fregni, I. Bartha, F. Muoio, K. Culap, N. Sprugasci, G. Lombardo, C. Saliba, E. Cameroni, A. Cassotta, J. S. Low, A. C. Walls, M. McCallum, M. A. Tortorici, , L. Piccoli

The paper examines the kinetics, avidity, and cross-reactivity of SARS-CoV-2-specific memory B cells and antibodies in infected and vaccinated individuals over 16 months, finding that MBC maturation enhances resilience to viral escape.

bioRxiv · Sep 30, 2022Immunology

Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains

T. N. Starr, A. J. Greaney, C. M. Stewart, A. C. Walls, W. W. Hannon, D. Veesler, J. D. Bloom

This study uses deep mutational scanning to analyze how mutations in the Omicron BA.1 and BA.2 RBDs affect ACE2 binding, RBD folding, and antibody escape, identifying epistatic shifts and lineage-specific changes.

bioRxiv · Sep 20, 2022Microbiology

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages

Y.-J. Park, D. Pinto, A. C. Walls, Z. Liu, A. De Marco, F. Benigni, F. Zatta, C. Silacci-Fregni, J. Bassi, K. R. Sprouse, A. Addetia, J. E. Bowen, C. Stewart, M. Giurdanella, C. Saliba, , Piccoli

This study shows that hybrid immunity and vaccine boosters provide potent neutralizing activity against Omicron BA.1 and BA.2, while breakthrough infections induce nasal mucosal neutralization and identify an ultrapotent pan-variant antibody.

bioRxiv · May 8, 2022Immunology

ACE2 engagement exposes the fusion peptide to pan-coronavirus neutralizing antibodies

J. S. Low, J. Jerak, M. A. Tortorici, M. McCallum, D. Pinto, A. Cassotta, M. Foglierini, F. Mele, R. Abdelnabi, B. Weynand, J. Noack, M. Montiel-Ruiz, S. Bianchi, F. Benigni, N. Sprugasci, , F. Sallusto

The paper identifies monoclonal antibodies that neutralize multiple coronaviruses by targeting the fusion peptide, which becomes exposed upon ACE2 engagement.

bioRxiv · Mar 30, 2022Immunology

Durable protection against SARS-CoV-2 Omicron induced by an adjuvanted subunit vaccine

P. S. Arunachalam, Y. Feng, U. Ashraf, M. Hu, V. V. Edara, V. I. Zarnitsyna, P. P. Aye, N. Golden, K. W. M. Green, B. M. Threeton, N. J. Maness, B. J. Beddingfield, R. P. Bohm, J. Dufour, K. Russell-Lodrigue, , B. Pulendran

This study shows that an adjuvanted subunit vaccine provides durable protection against SARS-CoV-2 Omicron in non-human primates, with strong neutralizing antibodies and memory T/B cells after booster doses.

bioRxiv · Mar 18, 2022 · PreprintImmunology

Omicron BA.1 and BA.2 neutralizing activity elicited by a comprehensive panel of human vaccines

J. E. Bowen, K. R. Sprouse, A. C. Walls, I. G. Mazzitelli, J. K. Logue, N. M. Franko, K. Ahmed, A. Shariq, E. Cameroni, A. Gori, A. Bori, C. M. Posavad, J. M. Dan, Z. Zhang, D. Weiskopf, , D. Veesler

This study evaluates neutralizing activity against Omicron BA.1 and BA.2 variants elicited by various vaccines and finds that booster doses enhance neutralizing titers and breadth across all vaccine platforms.

bioRxiv · Mar 15, 2022 · PreprintImmunology

Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice

A. C. Walls, L. A. VanBlargan, K. Wu, A. Choi, M. J. Navarro, D. Lee, L. Avena, D. M. Berrueta, M. N. Pham, S. Elbashir, M. C. Miranda, E. Kepl, M. Johnson, A. Blackstone, K. R. Sprouse, , D. Veesler

This study compares neutralizing antibody responses to SARS-CoV-2 variants in vaccinated humans and mice, finding that mice do not accurately reflect the breadth and potency seen in humans.

bioRxiv · Feb 7, 2022Immunology

Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail

A. Addetia, Y.-J. Park, T. Starr, A. J. Greaney, K. Sprouse, J. E. Bowen, S. W. Tiles, W. C. Van Voorhis, J. D. Bloom, D. Corti, A. C. Walls, D. Veesler

The paper examines structural changes in the SARS-CoV-2 spike E406W mutant that reduce neutralization by a monoclonal antibody cocktail and alters epitope recognition.

bioRxiv · Jan 21, 2022Biochemistry

SARS-CoV-2 spike conformation determines plasma neutralizing activity

J. E. Bowen, A. C. Walls, A. Joshi, K. R. Sprouse, C. Stewart, M. A. Tortorici, N. M. Franko, J. K. Logue, I. G. Mazzitelli, S. W. Tiles, K. Ahmed, A. Shariq, G. Snell, N. T. Iqbal, J. Geffner, , D. Veesler

This study shows that vaccines encoding a prefusion-stabilized SARS-CoV-2 spike protein induce higher neutralizing antibody titers and better variant cross-neutralization compared to other vaccines or infection.

bioRxiv · Dec 19, 2021 · PreprintImmunology

Delta breakthrough infections elicit potent, broad and durable neutralizing antibody responses

A. C. Walls, K. R. Sprouse, A. Joshi, J. E. Bowen, N. Franko, M.-J. Navarro, C. Stewart, M. McCallum, E. A. Goecker, E. J. Degli-Angeli, J. Logue, A. Greninger, H. Chu, D. Veesler

The paper examines antibody responses in Delta breakthrough infections, finding they are more potent, durable, and broad compared to vaccinated-only or infected-only individuals.

bioRxiv · Dec 8, 2021 · PreprintImmunology

Structure, receptor recognition and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein

M. A. Tortorici, A. C. Walls, A. Joshi, Y.-J. Park, R. T. Eguia, T. Stevens-Ayers, M. J. Boeckh, A. Talenti, A. Lanzavecchia, D. Corti, J. D. Bloom, D. Veesler

The paper determines the structure of the CCoV-HuPn-2018 spike glycoprotein, identifies its receptor, and shows cross-neutralizing antibodies against related coronaviruses.

bioRxiv · Oct 25, 2021Microbiology

Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry

Y.-J. Park, A. De Marco, T. N. Starr, Z. Liu, D. Pinto, A. C. Walls, F. Zatta, S. K. Zepeda, J. E. Bowen, K. S. Sprouse, A. Joshi, M. Giurdanella, B. Guarino, J. Noack, R. Abdelnabi, , D. Veesler

This study identifies a broadly neutralizing antibody against sarbecoviruses that targets the ACE2 binding site and shows high resistance to escape mutations.

bioRxiv · Oct 13, 2021Immunology

Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants

M. McCallum, A. C. Walls, K. R. Sprouse, J. E. Bowen, L. Rosen, H. V. Dang, A. deMarco, N. Franko, S. W. Tilles, J. Logue, M. C. Miranda, M. Ahlrichs, L. Carter, G. Snell, M. S. Pizzuto, , D. Veesler

This study investigates how delta and kappa SARS-CoV-2 variants evade immune responses by altering antigenic sites and reducing ACE2 binding affinity.

bioRxiv · Aug 11, 2021Immunology

ACE2 binding is an ancestral and evolvable trait of sarbecoviruses

T. N. Starr, S. K. Zepeda, A. C. Walls, A. J. Greaney, D. Veesler, J. D. Bloom

This study traces the evolutionary history of ACE2 binding in sarbecoviruses, finding it is an ancestral trait that has been lost in some clades and is highly evolvable through single amino-acid mutations.

bioRxiv · Jul 17, 2021Evolutionary Biology

Stabilization of the SARS-CoV-2 Spike receptor-binding domain using deep mutational scanning and structure-based design

D. Ellis, N. Brunette, K. H. D. Crawford, A. C. Walls, M. N. Pham, C. Chen, K.-L. Herpoldt, B. Fiala, M. Murphy, D. Pettie, J. C. Kraft, K. D. Malone, M. J. Navarro, C. Ogohara, E. Kepl, , N. P. King

This paper designs stabilized SARS-CoV-2 RBD variants using deep mutational scanning and structure-based design, showing improved thermal stability and manufacturability for vaccine applications.

bioRxiv · May 15, 2021Microbiology

A human antibody that broadly neutralizes betacoronaviruses protects against SARS-CoV-2 by blocking the fusion machinery

D. Pinto, M. M. Sauer, N. Czudnochowski, J. S. Low, M. A. Tortorici, M. P. Housley, J. Noack, A. C. Walls, J. E. Bowen, B. Guarino, L. E. Rosen, J. di Iulio, J. Jerak, H. Kaiser, S. Islam, , Lanzave

This paper identifies a human antibody that broadly neutralizes betacoronaviruses by targeting the stem helix, showing protection against SARS-CoV-2 and potential for vaccine design.

bioRxiv · May 9, 2021 · PreprintImmunology

Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody

M. A. Tortorici, N. Czudnochowski, T. N. Starr, R. Marzi, A. C. Walls, F. Zatta, J. E. Bowen, S. Jaconi, J. di Iulio, Z. Wang, A. De Marco, S. Zepeda, D. Pinto, Z. Liu, M. Beltramello, , J. Bloom

This paper identifies a human monoclonal antibody that broadly neutralizes SARS-CoV-2 variants and zoonotic sarbecoviruses by targeting a conserved epitope on the spike protein.

bioRxiv · Apr 7, 2021 · PreprintImmunology

Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodies

F. A. Lempp, L. Soriaga, M. Montiel-Ruiz, F. Benigni, J. Noack, Y.-J. Park, S. Bianchi, A. C. Walls, J. E. Bowen, J. Zhou, H. Kaiser, M. Agostini, M. Meury, E. Dellota, S. Jaconi, , D. Corti

This study identifies membrane lectins that enhance SARS-CoV-2 infection and show how different antibodies neutralize infection through distinct mechanisms.

bioRxiv · Apr 3, 2021 · PreprintMicrobiology

SARS-CoV-2 immune evasion by variant B.1.427/B.1.429

M. McCallum, J. Bassi, A. De Marco, A. Chen, A. C. Walls, J. Di Iulio, M. A. Tortorici, M.-J. Navarro, C. Silacci-Fregni, C. Saliba, M. Agostini, D. Pinto, K. Culap, S. Bianchi, S. Jaconi, , D. Veesler

This study evaluates how the B.1.427/B.1.429 SARS-CoV-2 variant evades neutralizing antibodies through mutations in the RBD and NTD, showing reduced neutralization by both vaccine-induced and infection-derived antibodies.

bioRxiv · Mar 31, 2021 · PreprintImmunology

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

A. C. Walls, M. C. Miranda, M. N. Pham, A. Schaefer, A. Greaney, P. S. Arunachalam, M.-J. Navarro, M. A. Tortorici, K. Rogers, M. A. O'Connor, L. Shireff, D. E. Ferrell, N. Brunette, E. Kepl, J. E. Bowen, , Veesler

This study shows that a SARS-CoV-2 RBD nanoparticle vaccine protects against SARS-CoV-2 and related sarbecoviruses, including variants, in mice and non-human primates.

bioRxiv · Mar 15, 2021Immunology

Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates

P. S Arunachalam, A. C. Walls, N. Golden, C. Atyeo, S. Fischinger, C. Li, P. Aye, M. J. Navarro, L. Lai, V. V. Edara, K. Roltgen, K. Rogers, L. Shirreff, D. E. Ferrell, S. Wrenn, , Coffma

This study evaluates adjuvants for a subunit SARS-CoV-2 nanoparticle vaccine in non-human primates, showing durable neutralizing antibody responses and protection against infection.

bioRxiv · Feb 10, 2021 · PreprintImmunology

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

M. McCallum, A. De Marco, F. Lempp, M. A. Tortorici, D. Pinto, A. C. Walls, M. Beltramello, A. Chen, Z. Liu, F. Zatta, S. Zepeda, J. di Iulio, J. E. Bowen, M. Montiel-Ruiz, J. Zhou, , D. Veesler

The paper identifies a conserved antigenic supersite on the SARS-CoV-2 N-terminal domain recognized by neutralizing antibodies and shows its vulnerability to mutations in variants.

bioRxiv · Jan 14, 2021Immunology

Structural basis for broad coronavirus neutralization

M. Sauer, Y.-J. Park, M. A. Tortorici, A. C. Walls, L. Homad, O. Acton, J. E. Bowen, C. Wang, X. Xiong, W. de van der Schueren, J. Quispe, B.-J. Bosch, B. G. Hoffstrom, A. T. McGuire, D. Veesler

This study identifies a monoclonal antibody that broadly neutralizes multiple beta-coronaviruses by targeting a conserved epitope, providing a structural basis for designing pan-coronavirus vaccines.

bioRxiv · Dec 29, 2020Biochemistry

Designed proteins assemble antibodies into modular nanocages

R. Divine, H. V. Dang, G. Ueda, J. A. Fallas, I. Vulovic, W. Sheffler, S. Saini, Y. T. Zhao, I. X. Raj, P. A. Morawski, M. F. Jennewein, L. J. Homad, Y.-H. Wan, M. R. Tooley, F. Seeger, , D. Baker

The paper designs modular nanocages that assemble antibodies into precise geometries, enhancing signaling and neutralization compared to free antibodies.

bioRxiv · Dec 1, 2020Biochemistry

Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2

A. C. Walls, B. Fiala, A. Schaefer, S. Wrenn, M. N. Pham, M. Murphy, L. V. Tse, L. Shehata, M. A. O'Connor, C. Chen, M. J. Navarro, M. C. Miranda, D. Pettie, R. Ravichandran, J. C. Kraft, , N. P. King

This study designs SARS-CoV-2 nanoparticle vaccines that induce strong neutralizing antibodies in mice, with higher titers and lower doses than existing trimer vaccines.

bioRxiv · Aug 11, 2020Immunology

Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding

T. N. Starr, A. J. Greaney, S. K. Hilton, K. H. Crawford, M. J. Navarro, J. E. Bowen, M. A. Tortorici, A. C. Walls, D. Veesler, J. D. Bloom

The paper experimentally measures the effects of all amino-acid mutations in the SARS-CoV-2 RBD on protein folding and ACE2 binding, identifying constrained regions and tolerated mutations.

bioRxiv · Jun 17, 2020Microbiology

Closing coronavirus spike glycoproteins by structure-guided design

M. McCallum, A. C. Walls, D. Corti, D. Veesler

This paper designs a stabilized SARS-CoV-2 spike glycoprotein in the closed conformation, showing it maintains structure and antigenicity while being applicable to other beta-coronaviruses.

bioRxiv · Jun 3, 2020 · PreprintBiochemistry

Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates

J. H. Erasmus, A. P. Khandhar, A. C. Walls, E. A. Hemann, M. A. O'Connor, P. Murapa, J. Archer, S. Leventhal, J. Fuller, T. Lewis, K. E. Draves, S. Randall, K. A. Guerriero, M. S. Duthie, D. Carter, , D. H. Fuller

bioRxiv · May 28, 2020 · PreprintImmunology

Structural and functional analysis of a potent sarbecovirus neutralizing antibody

D. Pinto, Y.-J. Park, M. Beltramello, A. C. Walls, M. A. Tortorici, S. Bianchi, S. Jaconi, K. Culap, F. Zatta, A. De Marco, A. Peter, B. Guarino, R. Spreafico, E. Cameroni, J. B. Case, , D. Corti

This study identifies and characterizes a potent neutralizing antibody, S309, against SARS-CoV-2 and related sarbecoviruses, showing its efficacy in preventing viral entry and potential for therapeutic use.

bioRxiv · Apr 7, 2020Immunology